The candidate addresses a significant medical gap in treating dry age-related macular degeneration (AMD), uveitis, and dry eye disease. By leveraging structure-based drug design, Insilico developed a molecule that provides superior retinal tissue exposure and high permeability compared to existing therapies. Preclinical models showed that ISM9077 outperformed current standards, including Cyclosporine A, in both corneal inflammation suppression and visual function recovery.
Insilico Medicine Unveils AI-Designed Candidate for Ocular Disease
Insilico Medicine has nominated ISM9077 as a preclinical candidate, marking the 32nd drug discovery milestone for the company since 2021. Designed via the Chemistry42 generative AI platform, the molecule functions as a first-in-class Target Y inhibitor, potentially offering a non-invasive eye drop treatment for chronic ocular conditions.
Beyond its primary ocular focus, ISM9077 is categorized as a pipeline-in-a-drug candidate due to its ability to modulate pathological inflammation. This mechanism suggests broad therapeutic potential for age-related and inflammatory conditions, such as neurodegenerative diseases, obesity, and cardiovascular disorders. Alex Zhavoronkov, CEO of Insilico Medicine, emphasized that the candidate aligns with the company’s dual-purpose strategy of treating specific pathologies while simultaneously targeting biological aging. With the global ocular disease market projected to reach $71.58 billion by 2034, the company aims to move ISM9077 toward clinical translation, banking on its favorable safety profile and potential for both oral and topical delivery.
Comments (0)
No comments yet. Be the first!